Last reviewed · How we verify
Abrysvo (abrysvo)
ABRYSVO is a vaccine that protects against respiratory syncytial virus (RSV).
Abrysvo, developed by Pfizer, holds a significant market position as the world's best-selling RSV vaccine, generating $1.033 billion in revenue. Its competitive advantage lies in its robust efficacy and safety profile, setting it apart from other RSV treatments like Ribavirin, Synagis, Arexvy, Virazole, and Nirsevimab. A key risk is the lack of clinical trial data to support further indications, which may limit its expansion into new markets. Despite this, the pipeline outlook remains promising, with potential for additional indications that could further solidify its market leadership.
At a glance
| Generic name | abrysvo |
|---|---|
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | RSV |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| Annual revenue | 1033 |
Mechanism of action
ABRYSVO is a vaccine designed to protect against respiratory syncytial virus (RSV). RSV is a highly contagious virus that affects people of all ages, but it is most severe in young children and older adults. The virus causes inflammation in the lungs and airways, leading to symptoms such as coughing, wheezing, and difficulty breathing. ABRYSVO works by stimulating the body's immune system to produce antibodies that can recognize and fight RSV.
Approved indications
- Prevention of rabies in individuals who have been bitten or otherwise exposed to rabies or have been at risk of rabies exposure and have been vaccinated with a cell culture vaccine or an inactivated rabies vaccine.
Common side effects
- Pain at the injection site
- Headache
- Muscle pain
- Nausea
- Fatigue
- Joint pain
- Headache (60+ years)
- Muscle pain (18-59 years with chronic conditions)
- Pain at the injection site (18-59 years with chronic conditions)
- Nausea (18-59 years with chronic conditions)
- Pain at the injection site (60+ years)
- Muscle pain (60+ years)
Drug interactions
- Warfarin
- P-glycoprotein inducers
- P-glycoprotein inhibitors
- Strong CYP3A4 inducers
- Strong CYP3A4 inhibitors
- CYP3A4 substrates
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abrysvo CI brief — competitive landscape report
- Abrysvo updates RSS · CI watch RSS
- Pfizer portfolio CI